title: Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases.
abstract: A number of signaling pathways might be frequently disrupted in acute myeloid leukemia (AML). We questioned whether the dual SRC/ABL kinase inhibitor dasatinib can affect AML cells and whether differences can be observed with normal CD34(+) cells. First, we demonstrated that normal cord blood (CB) CD34(+) cells were unaffected by dasatinib at a low concentration (0.5 nM) in the long-term culture on MS5 stromal cells. No changes were observed in proliferation, differentiation, and colony formation. In a subset of AML cases (3/15), a distinct reduction in cell proliferation was observed, ranging from 48% to 91% inhibition at 0.5 nM of dasatinib, in particular, those characterized by BCR-ABL or KIT mutations. Moreover, the inhibitory effects of dasatinib were cytokine specific. Stem cell factor-mediated proliferation was significantly impaired, associated with a reduced phosphorylation of ERK1/2 and STAT5, whereas no effect was observed on interleukin-3 and thrombopoietin-mediated signaling despite SRC activation. In conclusion, this study demonstrates that dasatinib is a potential inhibitor in a subgroup of AML, especially those that express BCR-ABL or KIT mutations.
authors.affiliation: Department of Hematology, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands.
authors.forename: Lina
authors.initials: L
authors.lastname: Han
authors.forename: Jan Jacob
authors.initials: JJ
authors.lastname: Schuringa
authors.forename: André
authors.initials: A
authors.lastname: Mulder
authors.forename: Edo
authors.initials: E
authors.lastname: Vellenga
mesh_terms: D018952:Antigens, CD34 / Q000096:biosynthesis; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D000069439:Dasatinib; D005312:Fetal Blood / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007231:Infant, Newborn; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D013234:Stem Cells / Q000187:drug effects* / Q000473:pathology*; D017154:Stromal Cells / Q000187:drug effects / Q000473:pathology; D013844:Thiazoles / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D018952:Antigens, CD34; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D019009:Proto-Oncogene Proteins c-kit; D000069439:Dasatinib
references.citation: Cancer. 2006 Oct 15;107(8):1918-29
references.pmid: 16986126
references.citation: Blood. 2006 Jun 1;107(11):4532-9
references.pmid: 16469872
references.citation: Nat Med. 1997 Jul;3(7):730-7
references.pmid: 9212098
references.citation: Biochem J. 2008 Oct 15;415(2):241-5
references.pmid: 18588518
references.citation: Leuk Res. 2009 May;33(5):735-41
references.pmid: 18986703
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5869-78
references.pmid: 17020995
references.citation: Blood. 2000 Jan 15;95(2):726-7
references.pmid: 10660321
references.citation: Oncogene. 2002 May 13;21(21):3334-58
references.pmid: 12032773
references.citation: Blood. 1998 Jul 15;92(2):596-9
references.pmid: 9657760
references.citation: Blood. 2008 Feb 15;111(4):2269-79
references.pmid: 18056483
references.citation: Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2349-54
references.pmid: 17284614
references.citation: Oncogene. 2007 Jun 14;26(28):4179-88
references.pmid: 17213809
references.citation: Oncogene. 2004 Oct 18;23(48):7957-68
references.pmid: 15489913
references.citation: Leuk Res. 2004 May;28 Suppl 1:S21-8
references.pmid: 15036938
references.citation: Br J Haematol. 1995 Apr;89(4):805-11
references.pmid: 7772516
references.citation: Leukemia. 2008 Sep;22(9):1792-4
references.pmid: 18385756
references.citation: Blood. 2003 Jan 15;101(2):690-8
references.pmid: 12509383
references.citation: Leukemia. 2007 Mar;21(3):403-10
references.pmid: 17230226
references.citation: Annu Rev Genomics Hum Genet. 2002;3:179-98
references.pmid: 12194988
references.citation: J Clin Oncol. 2006 Aug 20;24(24):3904-11
references.pmid: 16921041
references.citation: Methods Mol Biol. 2009;538:287-300
references.pmid: 19277587
references.citation: J Exp Med. 2004 Sep 6;200(5):623-35
references.pmid: 15353555
references.citation: Leukemia. 2005 Jul;19(7):1267-9
references.pmid: 15858616
references.citation: Cancer Res. 2006 Jan 1;66(1):473-81
references.pmid: 16397263
references.citation: Exp Hematol. 2005 Apr;33(4):469-79
references.pmid: 15781338
references.citation: Haematologica. 2004 Aug;89(8):920-5
references.pmid: 15339674
references.citation: Blood. 2007 May 1;109(9):4006-15
references.pmid: 17218385
references.citation: Nature. 1994 Feb 17;367(6464):645-8
references.pmid: 7509044
references.citation: Leuk Res. 2008 Jun;32(6):913-8
references.pmid: 17928050
references.citation: Mol Cancer Ther. 2007 Apr;6(4):1400-5
references.pmid: 17431118
references.citation: Crit Rev Oncol Hematol. 2007 Sep;63(3):215-30
references.pmid: 17658267
references.citation: Pediatr Blood Cancer. 2008 Jun;50(6):1198-206
references.pmid: 17914733
references.citation: Leukemia. 1997 Oct;11(10):1605-9
references.pmid: 9324277
references.citation: Exp Hematol. 2008 May;36(5):655-66
references.pmid: 18346837
references.citation: Exp Hematol. 2007 Oct;35(10):1538-49
references.pmid: 17889721
references.citation: J Immunol. 2008 Feb 15;180(4):2045-53
references.pmid: 18250409
references.citation: J Med Chem. 2004 Dec 30;47(27):6658-61
references.pmid: 15615512
references.citation: Clin Cancer Res. 2008 Apr 1;14(7):1926-30
references.pmid: 18381929
references.citation: Mutat Res. 2005 May 2;572(1-2):1-13
references.pmid: 15790486